
Imatinib mesylate 400mg Tablet
Salt Composition: Imatinib mesylate
Expiry Date: 01/2028
Inclusive of all taxes
3x10 tablet
About The Product
Blood Cancer
Imatinib mesylate 400mg Tablet belongs to a class of medication known as tyrosine kinase inhibitors. It is an anticancer medicine that is commonly prescribed to treat certain blood cancers like chronic myeloid leukemia & acute lymphocytic leukemia, and gastrointestinal stromal tumors. It works as a specific inhibitor of several tyrosine kinase enzymes. After the oral administration, the effect of this medicine can be observed in 2-4 hours.
Side Effects
Like any other medicine, Imatinib mesylate 400mg Tablet also has some adverse effects on the body, and most of them are manageable without special medical attention.
Some common side effects include:
- Difficulty in breathing
- Indigestion
- Constipation
- Weight loss
- Acidic stomach
- Change in taste
- Dry mouth
- Joint pain
- Irregular heartbeat
- Unusual bleeding
- Presence of blood in coughing
- Abdominal pain.
- Swelling around the eyes
Do not forget to discuss the risks and benefits of this medication with your doctor. Seek medical attention immediately in case of any severe issues.
How To Use
- TakeImatinib mesylate 400mg Tablet as prescribed by your doctor.
- Swallow it as a whole with water and don't chew, crush, or break it.
- This tablet should be taken with food. Take it at the same time every day for effective results.
Safety Advice
Missed Doses
- It is advisable not to miss a dose of Imatinib 400mg Tablet .
- If you miss a scheduled dose of this medicine, contact your doctor immediately.
FAQs
Imatinib tablet is used to treat certain types of cancer, such as chronic myeloid leukemia, acute lymphocytic leukemia, and gastrointestinal stromal tumors.
Reference
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf
- Cohen, M. H., Johnson, J. R., & Pazdur, R. (2005). US Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clinical cancer research, 11(1), 12-19 - https://www.semanticscholar.org/paper/U.S.-Food-and-Drug-Administration-Drug-Approval-of-Cohen-Johnson/dd03728666a054549c5c1d9b7fecd81afee95fda
- Nikolova, Z., Peng, B., Hubert, M., Seiberling, M., Keller, U., Ho, Y. Y., ... & Capdeville, R. (2004). Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Cancer chemotherapy and pharmacology, 53(5), 433-438.
- Devi, N. A., Hadi, M. A., Rajitha, P., Sharma, J. V. C., & Rao, A. S. (2013). Formulation and evaluation of floating controlled release tablets of imatinib mesylate using hydrophilic matrix system. Int J Pharm Pharm Sci, 5(1), 271-277.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
